FRISCO, Texas / Sep 23, 2025 / Business Wire / Addus HomeCare Corporation (Nasdaq: ADUS), a provider of home care services, today announced that Dirk Allison, Chairman and Chief Executive Officer, and Brian Poff, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Jefferies 2025 Healthcare Services Conference, September 29 - 30, 2025, in Nashville, Tennessee.
In connection with the conference, there will be a live broadcast and replay of the Company’s presentation available under the Investor Relations section of the Company’s website, www.addus.com, starting at 9:20 a.m. Central Time / 10:20 a.m. Eastern Time on Tuesday, September 30, 2025. An online replay will also be available on the Company’s website for one month, beginning approximately one hour following the conclusion of the live broadcast.
About Addus HomeCare
Addus HomeCare is a provider of home care services that primarily include personal care services that assist with activities of daily living, as well as hospice and home health services. Addus HomeCare’s consumers are primarily persons who, without these services, are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. Addus HomeCare’s payor clients include federal, state, and local governmental agencies, managed care organizations, commercial insurers, and private individuals. Addus HomeCare currently provides home care services to approximately 62,000 consumers through 260 locations across 23 states. For more information, please visit www.addus.com.
| Last Trade: | US$112.20 |
| Daily Change: | 1.10 0.99 |
| Daily Volume: | 135,072 |
| Market Cap: | US$2.070B |
November 03, 2025 August 04, 2025 | |

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load